The recently approved luspatercept, which targets the bone morphogenetic protein-SMAD signaling pathway, and momelotinib, a newer JAK1/JAK2 inhibitor with anemia-related efficacy, have shown benefits in managing anemia in myelofibrosis. Here, JAK2 is linked to myelofibrosis.